A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC
Clinical trial NCT04514835 · UNKNOWN
Trial details
- NCT number
- NCT04514835
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-01
- Primary completion
- 2022-01-31
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.